1.39
0.71%
-0.01
アフターアワーズ:
1.45
0.06
+4.32%
前日終値:
$1.40
開ける:
$1.42
24時間の取引高:
2.63M
Relative Volume:
2.20
時価総額:
$171.71M
収益:
$36.86M
当期純損益:
$-171.67M
株価収益率:
-0.9267
EPS:
-1.5
ネットキャッシュフロー:
$-171.05M
1週間 パフォーマンス:
-7.33%
1か月 パフォーマンス:
-41.35%
6か月 パフォーマンス:
-24.46%
1年 パフォーマンス:
-35.65%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
MRSN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
1.39 | 171.71M | 36.86M | -171.67M | -171.05M | -1.50 |
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-15 | 再開されました | Citigroup | Buy |
2024-03-19 | アップグレード | JP Morgan | Underweight → Neutral |
2024-02-29 | アップグレード | BTIG Research | Neutral → Buy |
2024-02-29 | アップグレード | Guggenheim | Neutral → Buy |
2024-02-29 | アップグレード | Wedbush | Neutral → Outperform |
2023-12-04 | アップグレード | Citigroup | Neutral → Buy |
2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2023-07-27 | ダウングレード | BTIG Research | Buy → Neutral |
2023-07-27 | ダウングレード | Citigroup | Buy → Neutral |
2023-07-27 | ダウングレード | Guggenheim | Buy → Neutral |
2023-07-27 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-07-27 | ダウングレード | Truist | Buy → Hold |
2023-07-27 | ダウングレード | Wedbush | Outperform → Neutral |
2023-06-16 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-06-15 | 開始されました | Guggenheim | Buy |
2023-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
2023-01-20 | 開始されました | Citigroup | Buy |
2022-11-21 | 開始されました | Truist | Buy |
2021-10-15 | 再開されました | BTIG Research | Buy |
2021-08-30 | 開始されました | H.C. Wainwright | Buy |
2021-03-31 | 開始されました | Credit Suisse | Neutral |
2020-12-03 | 開始されました | Stifel | Buy |
2020-09-29 | 再開されました | JP Morgan | Neutral |
2020-04-29 | 開始されました | BTIG Research | Buy |
2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
2019-03-11 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-11-14 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | 開始されました | Robert W. Baird | Outperform |
2018-03-19 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Mersana Therapeutics Inc (MRSN) 最新ニュース
Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha
BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St
Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat
Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com
Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - MSN
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
Mersana Therapeutics (FRA:0M4) Cash Flow from Operations : €-87.38 Mil (TTM As of Sep. 2024) - GuruFocus.com
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
Mersana Therapeutics (FRA:0M4) Median PS Value : €0.00 (As of Nov. 24, 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com Nigeria
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.02 Mil (As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Inc (MRSN) 財務データ
収益
当期純利益
現金流量
EPS
Mersana Therapeutics Inc (MRSN) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Bala Mohan | SVP, Chief Development Officer |
Oct 28 '24 |
Sale |
1.90 |
1,884 |
3,580 |
54,731 |
大文字化:
|
ボリューム (24 時間):